Brief: Axsome Therapeutics Acquires AZD7325, A Selective GABA-A Modulator For Treatment Of Epilepsy
06/11/2025 12:29
Nov 6 (Reuters) - Axsome Therapeutics Inc AXSM.O: AXSOME THERAPEUTICS ACQUIRES SUBTYPE SELECTIVE GABA-A RECEPTOR POSITIVE ALLOSTERIC MODULATOR AZD7325 FOR THE TREATMENT OF EPILEPSY AXSOME THERAPEUTICS INC - OBTAINS EXCLUSIVE GLOBAL RIGHTS TO AZD7325 AXSOME THERAPEUTICS INC - TO BEGIN PHASE 2 TRIAL ACTIVITIES FOR AZD7325 IN 2026 Source text: ID:nGNX8Rwsfs Further company coverage: AXSM.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Axsome Therapeutics
See all newsUS RESEARCH ROUNDUP-Bright Minds Biosciences, Marvell Technology, Oracle Corporation
Axsome Therapeutics Q3 revenue rises on Auvelity and Sunosi
US RESEARCH ROUNDUP-Apple, Kaiser Aluminum, Reliance
Axsome Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Axsome Therapeutics Q2 revenue rises on AUVELITY growth